A new hope for idiopathic pulmonary fibrosis.

The New England journal of medicine 20140529

A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

The New England journal of medicine 20140529

Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.

Toxicology and applied pharmacology 20140115

Antifibrotic effect of atorvastatin on paraquat-induced pulmonary fibrosis: role of PPARγ receptors.

European journal of pharmacology 20131115

Chronic potentiation of cardiac L-type Ca(2+) channels by pirfenidone.

Cardiovascular research 20121101

Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogen-activated protein kinase signaling pathway.

Shock (Augusta, Ga.) 20121101

Effects of an anti-transforming growth factor-β agent (pirfenidone) on strabismus surgery in rabbits.

Current eye research 20120901

The big clinical trials in idiopathic pulmonary fibrosis.

Current opinion in pulmonary medicine 20120901

Into the matrix: targeting fibroblasts in pulmonary fibrosis.

Current opinion in pulmonary medicine 20120901

Effect of pirfenidone on pulmonary fibrosis due to paraquat poisoning in rats.

Clinical toxicology (Philadelphia, Pa.) 20120901

Pirfenidone treatment in idiopathic pulmonary fibrosis: too much of a great expectation?

The European respiratory journal 20120901

Genotoxic evaluation of pirfenidone using erythrocyte rodent micronucleus assay.

Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20120801

2012 update on diabetic kidney disease: the expanding spectrum, novel pathogenic insights and recent clinical trials.

Minerva medica 20120801

Inhibitory effects of pirfenidone on dendritic cells and lung allograft rejection.

Transplantation 20120727

Treating idiopathic pulmonary fibrosis: current opportunities and future challenges.

The clinical respiratory journal 20120701

Pirfenidone: significant treatment effects in idiopathic pulmonary fibrosis.

The clinical respiratory journal 20120701

Re: A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients.

Annals of plastic surgery 20120701

Update in diffuse parenchymal lung disease 2011.

American journal of respiratory and critical care medicine 20120701

Clinical highlights from the 2011 ERS Congress in Amsterdam.

The European respiratory journal 20120601

Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis.

European respiratory review : an official journal of the European Respiratory Society 20120601

Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis.

European respiratory review : an official journal of the European Respiratory Society 20120601

Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes.

European respiratory review : an official journal of the European Respiratory Society 20120601

Simultaneous determination of dextromethorphan and dextrophan in rat plasma by LC-MS/MS and its application to a pharmacokinetic study.

Die Pharmazie 20120601

Immunotherapy in miscellaneous medical disorders Graves ophthalmopathy, asthma, and regional painful syndrome.

The Medical clinics of North America 20120501

p38γ mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription.

The Journal of biological chemistry 20120427

Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction.

Archives of dermatological research 20120401

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Therapeutic advances in respiratory disease 20120401

Synthesis and structure-activity relationship of 5-substituent-2(1H)-pyridone derivatives as anti-fibrosis agents.

Bioorganic & medicinal chemistry letters 20120315

Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis.

European journal of pharmacology 20120305

Management of idiopathic pulmonary fibrosis.

Clinics in chest medicine 20120301

[Idiopathic pulmonary fibrosis: modern guideline-concordant diagnostics and innovative treatment].

Deutsche medizinische Wochenschrift (1946) 20120301

Drugs of the future for Peyronie's disease.

Medical hypotheses 20120201

Design, synthesis and antifibrotic activities of carbohydrate-modified 1-(substituted aryl)-5-trifluoromethyl-2(1H) pyridones.

Molecules (Basel, Switzerland) 20120117

A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients.

Annals of plastic surgery 20120101

The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.

Hypertension research : official journal of the Japanese Society of Hypertension 20120101

Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy.

PLoS pathogens 20120101

[Chronic kidney disease, new therapeutic approaches].

La Revue du praticien 20120101

Smoking and idiopathic pulmonary fibrosis.

Pulmonary medicine 20120101

Active roles of tumor stroma in breast cancer metastasis.

International journal of breast cancer 20120101

Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19.

Molecular vision 20120101

Therapeutic potential of ginger against renal injury induced by carbon tetrachloride in rats.

TheScientificWorldJournal 20120101

Pirfenidone inhibits TGF-β1-induced over-expression of collagen type I and heat shock protein 47 in A549 cells.

BMC pulmonary medicine 20120101

Antioxidants in kidney diseases: the impact of bardoxolone methyl.

International journal of nephrology 20120101

Antifibrotic effects of pirfenidone in rat proximal tubular epithelial cells.

Renal failure 20120101

Current and novel drug therapies for idiopathic pulmonary fibrosis.

Drug design, development and therapy 20120101

Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials.

PloS one 20120101

Clinical, molecular, and cellular features of non-Puerto Rican Hermansky-Pudlak syndrome patients of Hispanic descent.

The Journal of investigative dermatology 20111201

[Innovative therapeutics for idiopathic pulmonary fibrosis].

Presse medicale (Paris, France : 1983) 20111201

Design, synthesis and biological activity of original pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives as novel dual Nox4/Nox1 inhibitors.

Bioorganic & medicinal chemistry 20111201

[Role of medical treatment for symptomatic leiomyoma management in premenopausal women].

Journal de gynecologie, obstetrique et biologie de la reproduction 20111201

[Treatment of pulmonary fibrosis. New substances and new interventions].

Der Internist 20111201

Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-beta/Smads signaling in human proximal tubular epithelial cells.

Die Pharmazie 20111201

Pirfenidone: in idiopathic pulmonary fibrosis.

Drugs 20110910

Newer modes of treating interstitial lung disease.

Current opinion in pulmonary medicine 20110901

A first step against idiopathic pulmonary fibrosis.

European respiratory review : an official journal of the European Respiratory Society 20110901

Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?

European respiratory review : an official journal of the European Respiratory Society 20110901

Fluorofenidone attenuates renal interstitial fibrosis in the rat model of obstructive nephropathy.

Molecular and cellular biochemistry 20110801

Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program.

Expert review of respiratory medicine 20110801

Pirfenidone.

Nature reviews. Drug discovery 20110701

Pirfenidone for the treatment of Hermansky-Pudlak syndrome pulmonary fibrosis.

Molecular genetics and metabolism 20110601

Pirfenidone for diabetic nephropathy.

Journal of the American Society of Nephrology : JASN 20110601

[Interstitial lung disease].

Deutsche medizinische Wochenschrift (1946) 20110601

Trials and tribulations of new agents, novel biomarkers, and retarding renal progression.

Journal of the American Society of Nephrology : JASN 20110601

Antifibrotic activities of pirfenidone in animal models.

European respiratory review : an official journal of the European Respiratory Society 20110601

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Lancet (London, England) 20110521

Pirfenidone for idiopathic pulmonary fibrosis.

Lancet (London, England) 20110521

Evaluation of pirfenidone as a new postoperative antiscarring agent in experimental glaucoma surgery.

Investigative ophthalmology & visual science 20110516

Novel therapeutic approaches for pulmonary fibrosis.

British journal of pharmacology 20110501

Update on potential medical treatments for encapsulating peritoneal sclerosis; human and experimental data.

International urology and nephrology 20110301

[The study of effects of pirfenidone on the pulmonary fibrosis induced by paraquat in mice].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 20110201

Scarred by disease.

Nature medicine 20110101

Pirfenidone treatment of idiopathic pulmonary fibrosis.

Therapeutics and clinical risk management 20110101

A massive abdominal wall desmoid tumor occurring in a laparotomy scar: a case report.

World journal of surgical oncology 20110101

A Regenerative Antioxidant Protocol of Vitamin E and α-Lipoic Acid Ameliorates Cardiovascular and Metabolic Changes in Fructose-Fed Rats.

Evidence-based complementary and alternative medicine : eCAM 20110101

The protective effect of Malva sylvestris on rat kidney damaged by vanadium.

Lipids in health and disease 20110101

A rare cause of interstitial lung disease: Hermansky-Pudlak syndrome.

Tuberkuloz ve toraks 20110101

Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice.

BMC cardiovascular disorders 20110101

Diffuse alveolar damage: a common phenomenon in progressive interstitial lung disorders.

Pulmonary medicine 20110101

Postoperative Acute Exacerbation of IPF after Lung Resection for Primary Lung Cancer.

Pulmonary medicine 20110101

Antifibrotic treatment and other new strategies for improving renal outcomes.

Contributions to nephrology 20110101

Decorin and colchicine as potential treatments for post-haemorrhagic ventricular dilatation in a neonatal rat model.

Neonatology 20110101

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.

Respiratory research 20110101

Role of TGF-β signaling in inherited and acquired myopathies.

Skeletal muscle 20110101

Pharmacokinetics of pirfenidone after topical administration in rabbit eye.

Molecular vision 20110101

An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition.

Lung India : official organ of Indian Chest Society 20110101

Stem cell therapy for idiopathic pulmonary fibrosis: a protocol proposal.

Journal of translational medicine 20110101

Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment.

Respiratory research 20110101

Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease.

Clinical medicine insights. Case reports 20110101

In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion.

PloS one 20110101

Safety of postoperative administration of human urinary trypsin inhibitor in lung cancer patients with idiopathic pulmonary fibrosis.

PloS one 20110101

[Idiopathic pulmonary fibrosis -- progress in sight].

Duodecim; laaketieteellinen aikakauskirja 20110101

The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress.

Current cardiology reviews 20101101

Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias.

Heart rhythm 20101001

[Pirfenidone diminishes SiO2 induced lung fibrosis in rats].

Zhonghua lao dong wei sheng zhi ye bing za zhi = Zhonghua laodong weisheng zhiyebing zazhi = Chinese journal of industrial hygiene and occupational diseases 20101001

Non-steroid agents for idiopathic pulmonary fibrosis.

The Cochrane database of systematic reviews 20100908

Oxidative stress and antioxidants in interstitial lung disease.

Current opinion in pulmonary medicine 20100901

Progress toward novel treatments for chronic kidney disease.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation 20100901

[Interstitial lung diseases - historical development, current status, future prospects].

Pneumologie (Stuttgart, Germany) 20100901

Pirfenidone in idiopathic pulmonary fibrosis.

The European respiratory journal 20100901

Staphylococcal enterotoxins.

Toxins 20100801

Current and future treatment options in idiopathic pulmonary fibrosis.

Inflammation & allergy drug targets 20100701

Regulatory watch: Surprise setback for lung fibrosis drug highlights trial challenges.

Nature reviews. Drug discovery 20100701

Pirfenidone in idiopathic pulmonary fibrosis.

Drugs of today (Barcelona, Spain : 1998) 20100701

Antifibrotic effect of Pirfenidone on orbital fibroblasts of patients with thyroid-associated ophthalmopathy by decreasing TIMP-1 and collagen levels.

Investigative ophthalmology & visual science 20100601

New pharmacological treatments for improving renal outcomes in diabetes.

Nature reviews. Nephrology 20100601

Investigational approaches to therapies for idiopathic pulmonary fibrosis.

Expert opinion on investigational drugs 20100601

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

Expert review of respiratory medicine 20100601

Molecular basis and current treatment for alcoholic liver disease.

International journal of environmental research and public health 20100501

Pirfenidone in idiopathic pulmonary fibrosis.

The European respiratory journal 20100401

Idiopathic pulmonary fibrosis and pirfenidone.

The European respiratory journal 20100401

FDA panel likes new treatment for idiopathic pulmonary fibrosis.

Managed care (Langhorne, Pa.) 20100401

Renoprotective properties of pirfenidone in subtotally nephrectomized rats.

European journal of pharmacology 20100310

Inhibition of matrix deposition: a new strategy for prevention of restenosis after balloon angioplasty.

Journal of cardiovascular pharmacology 20100201

Pirfenidone: an anti-fibrotic therapy for progressive kidney disease.

Expert opinion on investigational drugs 20100201

Systemic myostatin inhibition via liver-targeted gene transfer in normal and dystrophic mice.

PloS one 20100101

Association between transforming growth factor beta1 polymorphisms and atrial fibrillation in essential hypertensive subjects.

Journal of biomedical science 20100101

Respiratory symptoms and disease characteristics as predictors of pulmonary function abnormalities in patients with rheumatoid arthritis: an observational cohort study.

Arthritis research & therapy 20100101

Clinical use of biomarkers of survival in pulmonary fibrosis.

Respiratory research 20100101

Interstitial lung diseases in children.

Orphanet journal of rare diseases 20100101

Interstitial lung disease in connective tissue diseases: evolving concepts of pathogenesis and management.

Arthritis research & therapy 20100101

The multifaceted role of pirfenidone and its novel targets.

Fibrogenesis & tissue repair 20100101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20100101

Insulin resistance and glycemic abnormalities are associated with deterioration of left ventricular diastolic function: a cross-sectional study.

Cardiovascular diabetology 20100101

Experimental models of duchenne muscular dystrophy: relationship with cardiovascular disease.

The open cardiovascular medicine journal 20100101

Inflammatory cytokines and atrial fibrillation: current and prospective views.

Journal of inflammation research 20100101

Alveolar macrophage dysregulation in Hermansky-Pudlak syndrome type 1.

American journal of respiratory and critical care medicine 20091201

Fibrogenesis in kidney transplantation: potential targets for prevention and therapy.

Transplantation 20091127

Pirfenidone inhibits carbon tetrachloride- and albumin complex-induced liver fibrosis in rodents by preventing activation of hepatic stellate cells.

Clinical and experimental pharmacology & physiology 20091001

Pirfenidone: a potential therapeutic option in the treatment of liver fibrosis.

Clinical and experimental pharmacology & physiology 20091001

Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamide adenine dinucleotide phosphate oxidase-dependent way in NRK-52E cells.

Nephrology (Carlton, Vic.) 20090901

Pirfenidone inhibits T-cell activation, proliferation, cytokine and chemokine production, and host alloresponses.

Transplantation 20090815

Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro.

Investigative ophthalmology & visual science 20090801

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.

Pulmonary pharmacology & therapeutics 20090801

Pirfenidone is renoprotective in diabetic kidney disease.

Journal of the American Society of Nephrology : JASN 20090801

Effects of intravenous administration of pirfenidone on horses with experimentally induced endotoxemia.

American journal of veterinary research 20090801

[Pharmacological properties and clinical effects of the antifibrotic agent pirfenidone (Pirespa) for treatment of idiopathic pulmonary fibrosis].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20090801

Recent advances in pharmacotherapy of atrial fibrillation.

Indian journal of pharmacology 20090801

Recent advances in the treatment of systemic sclerosis.

Clinical reviews in allergy & immunology 20090601

Established and newly proposed mechanisms of chronic cyclosporine nephropathy.

The Korean journal of internal medicine 20090601

Advances in understanding of idiopathic pulmonary fibrosis.

Chinese medical journal 20090405

Permutation test following covariate-adaptive randomization in randomized controlled trials.

Journal of biopharmaceutical statistics 20090101

Macrophage derived chemokine (CCL22), thymus and activation-regulated chemokine (CCL17), and CCR4 in idiopathic pulmonary fibrosis.

Respiratory research 20090101

Liver fibrosis secondary to bile duct injury: correlation of Smad7 with TGF-beta and extracellular matrix proteins.

BMC gastroenterology 20090101

Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model.

Radiation oncology (London, England) 20090101

New developments in the therapy of pulmonary fibrosis.

Advances in pharmacology (San Diego, Calif.) 20090101

The role of long-term doxycycline in patients of idiopathic pulmonaryfibrosis: The results of an open prospective trial.

Lung India : official organ of Indian Chest Society 20090101

Optimal treatment for idiopathic pulmonary fibrosis.

Thorax 20081201

Role of TGF-beta on cardiac structural and electrical remodeling.

Vascular health and risk management 20081201

Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy.

Hepatology international 20081201

Current and future anti-fibrotic therapies for chronic liver disease.

Clinics in liver disease 20081101

Potent antioxidant role of pirfenidone in experimental cirrhosis.

European journal of pharmacology 20081024

Fibrogenic polymorphisms (TGF-beta, PAI-1, AT) in Mexican patients with established liver fibrosis. Potential correlation with pirfenidone treatment.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research 20081001

Do drugs that block transforming growth factor beta reduce posthaemorrhagic ventricular dilatation in a neonatal rat model?

Acta paediatrica (Oslo, Norway : 1992) 20080901

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.

European journal of pharmacology 20080820

Superoxide scavenging activity of pirfenidone-iron complex.

Biochemical and biophysical research communications 20080718

Pharmacokinetics and clinical effects of pirfenidone administered intravenously in horses.

American journal of veterinary research 20080701

Acute exacerbation of idiopathic pulmonary fibrosis: a systematic review.

European journal of internal medicine 20080601

Effects of three anti-TNF-alpha drugs: etanercept, infliximab and pirfenidone on release of TNF-alpha in medium and TNF-alpha associated with the cell in vitro.

International immunopharmacology 20080501

Protective effects of pirfenidone on D-galactosamine and lipopolysaccharide-induced acute hepatotoxicity in rats.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20080401

Pharmacokinetics and metabolism of intravenous pirfenidone in sheep.

Biopharmaceutics & drug disposition 20080301

Pirfenidone inhibits the expression of HSP47 in TGF-beta1-stimulated human lung fibroblasts.

Life sciences 20080116

Pirfenidone prevents capsular contracture after mammary implantation.

Aesthetic plastic surgery 20080101

The role of aldosterone blockade in murine lupus nephritis.

Arthritis research & therapy 20080101

Idiopathic pulmonary fibrosis.

Orphanet journal of rare diseases 20080101

Aggressive juvenile fibromatosis of the paranasal sinuses: case report and brief review.

Journal of hematology & oncology 20080101

p63 - Key molecule in the early phase of epithelial abnormality in idiopathic pulmonary fibrosis.

Experimental and molecular pathology 20071201

Single- and multiple-dose pharmacokinetics of pirfenidone, an antifibrotic agent, in healthy Chinese volunteers.

Journal of clinical pharmacology 20071001

Do we have a pill for renal fibrosis?

Clinical journal of the American Society of Nephrology : CJASN 20070901

Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis.

Clinical journal of the American Society of Nephrology : CJASN 20070901

Pirfenidone: a novel potential therapeutic agent in the management of chronic allograft rejection.

Transplantation proceedings 20070901

Novel oral agents for multiple sclerosis.

Current neurology and neuroscience reports 20070501

Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas.

Pediatric neurology 20070501

Idiopathic pulmonary fibrosis.

The Journal of the Association of Physicians of India 20070501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20070401

Pirfenidone inhibits TGF-beta expression in malignant glioma cells.

Biochemical and biophysical research communications 20070309

A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone.

Muscle & nerve 20070201

Influence of pirfenidone on airway hyperresponsiveness and inflammation in a Brown-Norway rat model of asthma.

Pulmonary pharmacology & therapeutics 20070101

The role of PDGF in radiation oncology.

Radiation oncology (London, England) 20070101

Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.

PloS one 20070101

Oral pirfenidone in patients with chronic fibrosis resulting from radiotherapy: a pilot study.

Radiation oncology (London, England) 20070101

Evolving concepts of liver fibrogenesis provide new diagnostic and therapeutic options.

Comparative hepatology 20070101

Platelet-derived growth factor as a therapeutic target for systemic autoimmune diseases.

Drug target insights 20070101

Simple determination of pirfenidone in rat plasma via high-performance liquid chromatography.

Biomedical chromatography : BMC 20061201

Phase II trial of pirfenidone in adults with neurofibromatosis type 1.

Neurology 20061128

A pilot study in patients with established advanced liver fibrosis using pirfenidone.

Gut 20061101

Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure.

Circulation 20061017

Pirfenidone modulates airway responsiveness, inflammation, and remodeling after repeated challenge.

American journal of respiratory cell and molecular biology 20060901

Long-term administration of pirfenidone improves cardiac function in mdx mice.

Muscle & nerve 20060901

Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina.

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20060901

Novel pirfenidone analogues: synthesis of pyridin-2-ones for the treatment of pulmonary fibrosis.

Archiv der Pharmazie 20060801

Pirfenidone for the treatment of idiopathic pulmonary fibrosis.

Expert opinion on investigational drugs 20060701

[Newly developed therapeutic drugs for idiopathic interstitial pneumonias].

Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20060610

Promising pharmacologic innovations in treating pulmonary fibrosis.

Current opinion in pharmacology 20060601

Current perspectives on the treatment of idiopathic pulmonary fibrosis.

Proceedings of the American Thoracic Society 20060601

Pirfenidone: anti-fibrotic agent with a potential therapeutic role in the management of transplantation patients.

European journal of pharmacology 20060501

Microsphere-based protease assays and screening application for lethal factor and factor Xa.

Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

[Pulmonary fibrosis--a therapeutic dilemma?].

Medizinische Klinik (Munich, Germany : 1983) 20060415

Pirfenidone and chronic progressive obliterative airway disease.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20060401

Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach.

Clinics in chest medicine 20060301

EM703 improves bleomycin-induced pulmonary fibrosis in mice by the inhibition of TGF-beta signaling in lung fibroblasts.

Respiratory research 20060101

Pulmonary fibrosis in hermansky-pudlak syndrome. a case report and review.

Respiration; international review of thoracic diseases 20060101

Sequential testing for efficacy in clinical trials with non-transient effects.

Statistics in medicine 20051115

Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF.

American journal of respiratory and critical care medicine 20051101

The questionable efficacy of pirfenidone in IPF.

American journal of respiratory and critical care medicine 20051101

Pirfenidone for the treatment of idiopathic pulmonary fibrosis: therapeutic potential prompts further investigation.

Expert opinion on investigational drugs 20051101

Pirfenidone inhibits obliterative airway disease in mouse tracheal allografts.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation 20051001

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20051001

Pirfenidone inhibits inflammatory responses and ameliorates allograft injury in a rat lung transplant model.

The Journal of thoracic and cardiovascular surgery 20050901

Pirfenidone inhibits lung allograft fibrosis through L-arginine-arginase pathway.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20050601

Treatment of idiopathic pulmonary fibrosis: is there anything new?

Respirology (Carlton, Vic.) 20050601

[Drug treatments for idiopathic pulmonary fibrosis].

Revue de pneumologie clinique 20050601

The experimental agent pirfenidone reduces pro-fibrotic gene expression in a model of tacrolimus-induced nephrotoxicity.

The Journal of surgical research 20050515

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

American journal of respiratory and critical care medicine 20050501

Is idiopathic pulmonary fibrosis now treatable?

American journal of respiratory and critical care medicine 20050501

[Interstitial pneumonia].

Nihon rinsho. Japanese journal of clinical medicine 20050501

Protection of pirfenidone against an early phase of oleic acid-induced acute lung injury in rats.

The Journal of pharmacology and experimental therapeutics 20050401

A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20050401

Effect of pirfenidone on apoptosis-regulatory genes in chronic cyclosporine nephrotoxicity.

Transplantation 20050227

Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20050101

Retardation of kidney failure -- applying principles to practice.

Annals of the Academy of Medicine, Singapore 20050101

[Expectation of new treatments for idiopathic interstitial pneumonias].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics 20050101

The novel antifibrotic agent pirfenidone attenuates the profibrotic environment generated by calcineurin inhibitors in the rat salt-depletion model.

Transplantation proceedings 20050101

Primary progressive multiple sclerosis : current and future treatment options.

CNS drugs 20050101

Expression of HSP47 in usual interstitial pneumonia and nonspecific interstitial pneumonia.

Respiratory research 20050101

Symptomatic and disease-modifying therapies for multiple sclerosis: recent developments: highlights of the 9th Annual Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, October 3, 2004, Toronto, Ontario, Canada.

Reviews in neurological diseases 20050101

Effects of topical application of pirfenidone ointment on thermoplasty-induced acute lameness in a double-blind and acute and chronic lameness of musculoskeletal origin in an open multi-centered field trial in horses.

Research communications in molecular pathology and pharmacology 20050101

Transforming growth factor-beta: a clinical target for the treatment of diabetic nephropathy.

Current diabetes reports 20041201

Pirfenidone inhibits the induction of iNOS stimulated by interleukin-1beta at a step of NF-kappaB DNA binding in hepatocytes.

Journal of hepatology 20041101

The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1(I), TIMP-1 and MMP-2.

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20041101

Pharmacokinetics of orally administered pirfenidone in male and female beagles.

Journal of veterinary pharmacology and therapeutics 20041001

Pirfenidone protects endotoxin-induced liver injury after hepatic ischemia in rats.

Transplantation proceedings 20040901

Effects of pirfenidone on endotoxin-induced liver injury after partial hepatectomy in rats.

Transplantation proceedings 20040901

Effect of pirfenidone on induction of chemokines in rat hepatocytes.

Transplantation proceedings 20040901

Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy.

Expert opinion on pharmacotherapy 20040801

Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis.

The European respiratory journal 20040701

Potential nonhormonal therapeutics for medical treatment of leiomyomas.

Seminars in reproductive medicine 20040501

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20040501

Pirfenidone inhibits obliterative airway disease in a murine heterotopic tracheal transplant model.

Transplantation 20040315

New perspectives in treatment of glomerulonephritis.

Pediatric nephrology (Berlin, Germany) 20040301

Amelioration of doxorubicin-induced cardiac and renal toxicity by pirfenidone in rats.

Cancer chemotherapy and pharmacology 20040201

Pirfenidone.

IDrugs : the investigational drugs journal 20040201

Pirfenidone prevents endotoxin-induced liver injury after partial hepatectomy in rats.

Journal of hepatology 20040101

Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Drugs 20040101

Prevention of progressive fibrosis in chronic renal diseases: antifibrotic agents.

Journal of nephrology 20040101

Antirheumatic effect of pirfenidone in a double blind clinical pilot trial in humans.

Research communications in molecular pathology and pharmacology 20040101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20031201

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20031101

Differential effects of pirfenidone on acute pulmonary injury and ensuing fibrosis in the hamster model of amiodarone-induced pulmonary toxicity.

Toxicological sciences : an official journal of the Society of Toxicology 20030901

Desmoid tumors in familial adenomatous polyposis: a pilot project evaluating efficacy of treatment with pirfenidone.

The American journal of gastroenterology 20030801

Pirfenidone suppressed the development of glomerulosclerosis in the FGS/Kist mouse.

Journal of Korean medical science 20030801

Open-label study of pirfenidone in patients with progressive forms of multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20030601

Inhibition of experimental acute pulmonary inflammation by pirfenidone.

Pulmonary pharmacology & therapeutics 20030101

Modulation of articular chondrocyte activity by pirfenidone.

Research communications in molecular pathology and pharmacology 20030101

Pirfenidone effectively reverses experimental liver fibrosis.

Journal of hepatology 20021201

Open-label compassionate use one year-treatment with pirfenidone to patients with chronic pulmonary fibrosis.

Internal medicine (Tokyo, Japan) 20021201

Pirfenidone attenuates ischaemia-reperfusion injury in the rat small intestine.

Clinical and experimental pharmacology & physiology 20021101

Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production.

Journal of hepatology 20021101

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20021101

[Treatment of pulmonary fibrosis].

Presse medicale (Paris, France : 1983) 20021019

Gateways to clinical trials.

Methods and findings in experimental and clinical pharmacology 20021001

From anti-inflammatory drugs through antifibrotic agents to lung transplantation: a long road of research, clinical attempts, and failures in the treatment of idiopathic pulmonary fibrosis.

Chest 20020901

Effect of pirfenidone against vanadate-induced kidney fibrosis in rats.

Biochemical pharmacology 20020801

Pirfenidone inhibits early neointimal proliferation following arterial injury.

Transplantation proceedings 20020801

Pharmacokinetics and metabolism of a novel antifibrotic drug pirfenidone, in mice following intravenous administration.

Biopharmaceutics & drug disposition 20020701

Effect of pirfenidone on the pulmonary fibrosis of Hermansky-Pudlak syndrome.

Molecular genetics and metabolism 20020701

Pirfenidone suppresses tumor necrosis factor-alpha, enhances interleukin-10 and protects mice from endotoxic shock.

European journal of pharmacology 20020620

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor-alpha at the translational level.

European journal of pharmacology 20020620

Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B.

Infection and immunity 20020601

Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

The Journal of biological chemistry 20020419

Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats.

European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 20020301

Retinoic acid exacerbates experimental radiation nephropathy.

Radiation research 20020201

Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats.

British journal of pharmacology 20020201

Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20020201

Growth factors in idiopathic pulmonary fibrosis: relative roles.

Respiratory research 20020101

Pirfenidone in the treatment of primary sclerosing cholangitis.

Digestive diseases and sciences 20020101

Pirfenidone: A novel anti-fibrotic agent and progressive chronic allograft rejection.

Pulmonary pharmacology & therapeutics 20020101

Idiopathic pulmonary fibrosis: current and future treatment options.

American journal of respiratory medicine : drugs, devices, and other interventions 20020101

Antifibrotic therapy for the treatment of pulmonary fibrosis.

The American journal of the medical sciences 20011001

Pirfenidone for chronic progressive multiple sclerosis.

Multiple sclerosis (Houndmills, Basingstoke, England) 20011001

Modulation of airway remodeling-associated mediators by the antifibrotic compound, pirfenidone, and the matrix metalloproteinase inhibitor, batimastat, during acute lung injury in mice.

European journal of pharmacology 20010824

Pirfenidone inhibits dimethylnitrosamine-induced hepatic fibrosis in rats.

Clinical and experimental pharmacology & physiology 20010701

Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats.

British journal of pharmacology 20010701

A phase II trial of pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone), a novel anti-fibrosing agent, in myelofibrosis with myeloid metaplasia.

British journal of haematology 20010701

The balance between collagen synthesis and degradation in diffuse lung disease.

Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG 20010301

Effects of pirfenidone on vascular smooth muscle cell proliferation and intimal hyperplasia following arterial balloon injury.

Transplantation proceedings 20010101

Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis.

Journal of nephrology 20010101